Tapewire

Nasdaq · USD

ANIP

ANI PHARMACEUTICALS INC

Export transactions ↓
Tapewire entity
4638
SEC CIK
0001023024
Parsed reports
463

Last 12 months

Inside the activity.

0 purchase rows · 48 sale rows

Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.
Monthly counts
MonthPurchasesSales
Nov 202504
Dec 202503
Jan 202601
Feb 202605
Mar 2026012
Apr 202601
May 202606
Jun 202604
Jul 202603
Aug 202604
Sep 202604
Oct 202601

Latest available

Insider transactions

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateOwner / reported roleActivity / securityShares / unitsReported priceReported valueDetails
March 13, 2025 Filed Mar 14, 2025 21:28 UTC
Cook MeredithSR. VP, GENERAL COUNSEL & SEC.
SaleCommon Stock 400 $63.33 $25,332.00
Disclosure

SEC source: 0001938861-25-000008 · wk-form4_1741987671.xml · nonDerivative · entry 1

Cook Meredith · CIK 0001938861 · SR. VP, GENERAL COUNSEL & SEC.

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 80,545

F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 17, 2024.

Read SEC document
March 07, 2025 Filed Mar 11, 2025 00:28 UTC
Davis KristaSVP, CHIEF HR OFFICER
SaleCommon Stock 1,000 $60.86 $60,860.00
Disclosure

SEC source: 0001946439-25-000008 · wk-form4_1741652880.xml · nonDerivative · entry 1

Davis Krista · CIK 0001946439 · SVP, CHIEF HR OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 66,525

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 23, 2024.

Read SEC document
March 07, 2025 Filed Mar 14, 2025 21:22 UTC
Mutz ChristopherHEAD OF RARE DISEASE
Tax withholdingCommon Stock 2,874 $60.62 $174,221.88
Disclosure

SEC source: 0001846487-25-000006 · wk-form4_1741987349.xml · nonDerivative · entry 1

Mutz Christopher · CIK 0001846487 · HEAD OF RARE DISEASE

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 111,317

F1 · kind: Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 6,476 shares of restricted stock, the grant of which was previously reported.

Read SEC document
March 07, 2025 Filed Mar 14, 2025 21:20 UTC
Lalwani NikhilDirector · PRESIDENT & CEO
Tax withholdingCommon Stock 17,060 $60.62 $1,034,177.20
Disclosure

SEC source: 0001822629-25-000006 · wk-form4_1741987242.xml · nonDerivative · entry 1

Lalwani Nikhil · CIK 0001822629 · Director · PRESIDENT & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 485,634

F1 · kind: Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 33,352 shares of restricted stock, the grant of which was previously reported.

Read SEC document
March 07, 2025 Filed Mar 14, 2025 21:19 UTC
Gutwerg OriSVP, GENERICS
Tax withholdingCommon Stock 3,314 $60.62 $200,894.68
Disclosure

SEC source: 0001846478-25-000009 · wk-form4_1741987175.xml · nonDerivative · entry 1

Gutwerg Ori · CIK 0001846478 · SVP, GENERICS

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 90,778

F1 · kind: Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 6,476 shares of restricted stock, the grant of which was previously reported.

Read SEC document
March 07, 2025 Filed Mar 14, 2025 21:17 UTC Tax withholdingCommon Stock 5,150 $60.62 $312,193.00
Disclosure

SEC source: 0001674236-25-000006 · wk-form4_1741987072.xml · nonDerivative · entry 1

CAREY STEPHEN P. · CIK 0001674236 · SVP & CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 187,073

F1 · kind: Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 11,292 shares of restricted stock, the grant of which was previously reported.

Read SEC document
March 05, 2025 Filed Mar 7, 2025 21:09 UTC
Gutwerg OriSVP, GENERICS
Exercise / conversionStock Option (right to buy) · Derivative 300 $31.49 Strike: $31.49 $9,447.00
Disclosure

SEC source: 0001846478-25-000007 · wk-form4_1741381758.xml · derivative · entry 4

Gutwerg Ori · CIK 0001846478 · SVP, GENERICS

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,204

Underlying: Common Stock · 300 shares

Expires 2031-02-15

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: 25% of the total options vested on each of February 15, 2022, February 15, 2023, February 15, 2024, and February 15, 2025.

Read SEC document
March 05, 2025 Filed Mar 7, 2025 21:09 UTC
Gutwerg OriSVP, GENERICS
SaleCommon Stock 5,084 $60.00 $305,040.00
Disclosure

SEC source: 0001846478-25-000007 · wk-form4_1741381758.xml · nonDerivative · entry 3

Gutwerg Ori · CIK 0001846478 · SVP, GENERICS

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 94,092

F1 · price: The shares were sold in multiple trades at prices ranging from $60.00 to $60.03. The price reported above reflects the weighted average sales price.

Read SEC document
March 05, 2025 Filed Mar 7, 2025 21:09 UTC
Gutwerg OriSVP, GENERICS
SaleCommon Stock 300 $60.03 $18,009.00
Disclosure

SEC source: 0001846478-25-000007 · wk-form4_1741381758.xml · nonDerivative · entry 2

Gutwerg Ori · CIK 0001846478 · SVP, GENERICS

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 99,176

Read SEC document
March 05, 2025 Filed Mar 7, 2025 21:09 UTC
Gutwerg OriSVP, GENERICS
Exercise / conversionCommon Stock 300 $31.49 $9,447.00
Disclosure

SEC source: 0001846478-25-000007 · wk-form4_1741381758.xml · nonDerivative · entry 1

Gutwerg Ori · CIK 0001846478 · SVP, GENERICS

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 99,476

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
February 28, 2025 Filed Mar 4, 2025 22:15 UTC
Rowland Thomas AndrewSVP, HEAD - ESTABLISHED BRANDS
Tax withholdingCommon Stock 627 $61.89 $38,805.03
Disclosure

SEC source: 0001507496-25-000004 · wk-form4_1741126494.xml · nonDerivative · entry 1

Rowland Thomas Andrew · CIK 0001507496 · SVP, HEAD - ESTABLISHED BRANDS

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 45,465

F1 · kind: Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 2,171 shares of restricted stock, the grant of which was previously reported.

Read SEC document
February 28, 2025 Filed Mar 4, 2025 22:12 UTC
Mutz ChristopherHEAD OF RARE DISEASE
Tax withholdingCommon Stock 1,275 $61.89 $78,909.75
Disclosure

SEC source: 0001846487-25-000004 · wk-form4_1741126332.xml · nonDerivative · entry 1

Mutz Christopher · CIK 0001846487 · HEAD OF RARE DISEASE

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 114,191

F1 · kind: Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 4,342 shares of restricted stock, the grant of which was previously reported.

Read SEC document
February 28, 2025 Filed Mar 4, 2025 22:10 UTC
Lalwani NikhilDirector · PRESIDENT & CEO
Tax withholdingCommon Stock 12,216 $61.89 $756,048.24
Disclosure

SEC source: 0001822629-25-000004 · wk-form4_1741126197.xml · nonDerivative · entry 1

Lalwani Nikhil · CIK 0001822629 · Director · PRESIDENT & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 502,694

F1 · kind: Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 23,882 shares of restricted stock, the grant of which was previously reported.

Read SEC document
February 28, 2025 Filed Mar 4, 2025 22:07 UTC
Gutwerg OriSVP, GENERICS
Tax withholdingCommon Stock 1,570 $61.89 $97,167.30
Disclosure

SEC source: 0001846478-25-000005 · wk-form4_1741126058.xml · nonDerivative · entry 1

Gutwerg Ori · CIK 0001846478 · SVP, GENERICS

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 99,176

F1 · kind: Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 4,342 shares of restricted stock, the grant of which was previously reported.

Read SEC document
February 28, 2025 Filed Mar 4, 2025 22:06 UTC
Davis KristaSVP, CHIEF HR OFFICER
Tax withholdingCommon Stock 1,099 $61.89 $68,017.11
Disclosure

SEC source: 0001946439-25-000006 · wk-form4_1741125961.xml · nonDerivative · entry 1

Davis Krista · CIK 0001946439 · SVP, CHIEF HR OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 67,525

F1 · kind: Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 3,039 shares of restricted stock, the grant of which was previously reported.

Read SEC document
February 28, 2025 Filed Mar 4, 2025 22:04 UTC
Cook MeredithSR. VP, GENERAL COUNSEL & SEC.
Tax withholdingCommon Stock 1,099 $61.89 $68,017.11
Disclosure

SEC source: 0001938861-25-000006 · wk-form4_1741125873.xml · nonDerivative · entry 1

Cook Meredith · CIK 0001938861 · SR. VP, GENERAL COUNSEL & SEC.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 80,945

F1 · kind: Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 3,039 shares of restricted stock, the grant of which was previously reported.

Read SEC document
February 28, 2025 Filed Mar 4, 2025 22:03 UTC Tax withholdingCommon Stock 1,861 $61.89 $115,177.29
Disclosure

SEC source: 0001674236-25-000004 · wk-form4_1741125785.xml · nonDerivative · entry 1

CAREY STEPHEN P. · CIK 0001674236 · SVP & CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 192,223

F1 · kind: Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 6,079 shares of restricted stock, the grant of which was previously reported.

Read SEC document
February 21, 2025 Filed Feb 24, 2025 21:33 UTC
Davis KristaSVP, CHIEF HR OFFICER
SaleCommon Stock 1,000 $60.20 $60,200.00
Disclosure

SEC source: 0001946439-25-000004 · wk-form4_1740432806.xml · nonDerivative · entry 1

Davis Krista · CIK 0001946439 · SVP, CHIEF HR OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 68,624

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 23, 2024.

Read SEC document
February 15, 2025 Filed Feb 19, 2025 01:17 UTC
Mutz ChristopherHEAD OF RARE DISEASE
Tax withholdingCommon Stock 1,184 $58.92 $69,761.28
Disclosure

SEC source: 0001846487-25-000002 · wk-form4_1739927844.xml · nonDerivative · entry 4

Mutz Christopher · CIK 0001846487 · HEAD OF RARE DISEASE

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 115,466

F4 · kind: Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 4,034 shares of restricted stock, the grant of which was previously reported.

Read SEC document
February 15, 2025 Filed Feb 19, 2025 01:15 UTC
Gutwerg OriSVP, GENERICS
Tax withholdingCommon Stock 1,167 $58.92 $68,759.64
Disclosure

SEC source: 0001846478-25-000003 · wk-form4_1739927699.xml · nonDerivative · entry 4

Gutwerg Ori · CIK 0001846478 · SVP, GENERICS

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 100,746

F4 · kind: Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 3,227 shares of restricted stock, the grant of which was previously reported.

Read SEC document
February 14, 2025 Filed Feb 19, 2025 01:19 UTC
Rowland Thomas AndrewSVP, HEAD - ESTABLISHED BRANDS
Tax withholdingCommon Stock 582 $58.92 $34,291.44
Disclosure

SEC source: 0001507496-25-000002 · wk-form4_1739927941.xml · nonDerivative · entry 3

Rowland Thomas Andrew · CIK 0001507496 · SVP, HEAD - ESTABLISHED BRANDS

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 46,092

F4 · kind: Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 1,677 shares of restricted stock, the grant of which was previously reported.

Read SEC document
February 14, 2025 Filed Feb 19, 2025 01:17 UTC
Mutz ChristopherHEAD OF RARE DISEASE
Tax withholdingCommon Stock 1,473 $58.92 $86,789.16
Disclosure

SEC source: 0001846487-25-000002 · wk-form4_1739927844.xml · nonDerivative · entry 3

Mutz Christopher · CIK 0001846487 · HEAD OF RARE DISEASE

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 116,650

F3 · kind: Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 4,697 shares of restricted stock, the grant of which was previously reported.

Read SEC document
February 14, 2025 Filed Feb 19, 2025 01:16 UTC
Lalwani NikhilDirector · PRESIDENT & CEO
Tax withholdingCommon Stock 7,799 $58.92 $459,517.08
Disclosure

SEC source: 0001822629-25-000002 · wk-form4_1739927772.xml · nonDerivative · entry 3

Lalwani Nikhil · CIK 0001822629 · Director · PRESIDENT & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 514,910

F3 · kind: Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 20,132 shares of restricted stock, the grant of which was previously reported.

Read SEC document
February 14, 2025 Filed Feb 19, 2025 01:15 UTC
Gutwerg OriSVP, GENERICS
Tax withholdingCommon Stock 1,426 $58.92 $84,019.92
Disclosure

SEC source: 0001846478-25-000003 · wk-form4_1739927699.xml · nonDerivative · entry 3

Gutwerg Ori · CIK 0001846478 · SVP, GENERICS

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 101,913

F3 · kind: Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 3,690 shares of restricted stock, the grant of which was previously reported.

Read SEC document
February 14, 2025 Filed Feb 19, 2025 01:13 UTC
Davis KristaSVP, CHIEF HR OFFICER
Tax withholdingCommon Stock 1,196 $58.92 $70,468.32
Disclosure

SEC source: 0001946439-25-000002 · wk-form4_1739927578.xml · nonDerivative · entry 3

Davis Krista · CIK 0001946439 · SVP, CHIEF HR OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 69,624

F3 · kind: Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 3,019 shares of restricted stock, the grant of which was previously reported.

Read SEC document
February 14, 2025 Filed Feb 19, 2025 01:12 UTC
Cook MeredithSR. VP, GENERAL COUNSEL & SEC.
Tax withholdingCommon Stock 1,434 $58.92 $84,491.28
Disclosure

SEC source: 0001938861-25-000004 · wk-form4_1739927525.xml · nonDerivative · entry 4

Cook Meredith · CIK 0001938861 · SR. VP, GENERAL COUNSEL & SEC.

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 82,044

F4 · kind: Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 3,690 shares of restricted stock, the grant of which was previously reported.

Read SEC document
February 14, 2025 Filed Feb 19, 2025 01:11 UTC Tax withholdingCommon Stock 1,730 $58.92 $101,931.60
Disclosure

SEC source: 0001674236-25-000002 · wk-form4_1739927467.xml · nonDerivative · entry 3

CAREY STEPHEN P. · CIK 0001674236 · SVP & CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 194,084

F3 · kind: Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 5,368 shares of restricted stock, the grant of which was previously reported.

Read SEC document
February 13, 2025 Filed Feb 19, 2025 01:12 UTC
Cook MeredithSR. VP, GENERAL COUNSEL & SEC.
SaleCommon Stock 400 $59.54 $23,816.00
Disclosure

SEC source: 0001938861-25-000004 · wk-form4_1739927525.xml · nonDerivative · entry 3

Cook Meredith · CIK 0001938861 · SR. VP, GENERAL COUNSEL & SEC.

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 83,478

F3 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 17, 2024.

Read SEC document
February 12, 2025 Filed Feb 19, 2025 01:19 UTC
Rowland Thomas AndrewSVP, HEAD - ESTABLISHED BRANDS
GrantCommon Stock 5,222 $0.00 $0.00
Disclosure

SEC source: 0001507496-25-000002 · wk-form4_1739927941.xml · nonDerivative · entry 2

Rowland Thomas Andrew · CIK 0001507496 · SVP, HEAD - ESTABLISHED BRANDS

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 46,674

F3 · kind: These shares represent performance stock units, which will vest over the applicable performance period based on the achievement of the provided performance targets, as set forth in the governing award agreement, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting.

Read SEC document
February 12, 2025 Filed Feb 19, 2025 01:19 UTC
Rowland Thomas AndrewSVP, HEAD - ESTABLISHED BRANDS
GrantCommon Stock 7,834 $0.00 $0.00
Disclosure

SEC source: 0001507496-25-000002 · wk-form4_1739927941.xml · nonDerivative · entry 1

Rowland Thomas Andrew · CIK 0001507496 · SVP, HEAD - ESTABLISHED BRANDS

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 41,452

F1 · kind: Represents a restricted stock award that will vest in four equal annual installments on the first, second, third and fourth anniversaries of February 12, 2025.

F2 · balance_after: Includes 449 shares of ANI Pharmaceuticals, Inc. Common Stock that were acquired under the ANI Pharmaceuticals, Inc. Employee Stock Purchase Plan in transactions that were exempt under Rule 16b-3(d) and Rule 16b-3(c).

Read SEC document
February 12, 2025 Filed Feb 19, 2025 01:19 UTC
Shanmugam MuthusamyDirector · HEAD OF R&D, COO-NOVITIUM OPS
GrantCommon Stock 9,574 $0.00 $0.00
Disclosure

SEC source: 0001870913-25-000002 · wk-form4_1739927992.xml · nonDerivative · entry 2

Shanmugam Muthusamy · CIK 0001870913 · Director · HEAD OF R&D, COO-NOVITIUM OPS

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 92,588

F2 · kind: These shares represent performance stock units, which will vest over the applicable performance period based on the achievement of the provided performance targets, as set forth in the governing award agreement, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting.

Read SEC document
February 12, 2025 Filed Feb 19, 2025 01:19 UTC
Shanmugam MuthusamyDirector · HEAD OF R&D, COO-NOVITIUM OPS
GrantCommon Stock 14,362 $0.00 $0.00
Disclosure

SEC source: 0001870913-25-000002 · wk-form4_1739927992.xml · nonDerivative · entry 1

Shanmugam Muthusamy · CIK 0001870913 · Director · HEAD OF R&D, COO-NOVITIUM OPS

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 83,014

F1 · kind: Represents a restricted stock award that will vest in four equal annual installments on the first, second, third and fourth anniversaries of February 12, 2025.

Read SEC document
February 12, 2025 Filed Feb 19, 2025 01:17 UTC
Mutz ChristopherHEAD OF RARE DISEASE
GrantCommon Stock 16,538 $0.00 $0.00
Disclosure

SEC source: 0001846487-25-000002 · wk-form4_1739927844.xml · nonDerivative · entry 2

Mutz Christopher · CIK 0001846487 · HEAD OF RARE DISEASE

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 118,123

F2 · kind: These shares represent performance stock units, which will vest over the applicable performance period based on the achievement of the provided performance targets, as set forth in the governing award agreement, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting.

Read SEC document
February 12, 2025 Filed Feb 19, 2025 01:17 UTC
Mutz ChristopherHEAD OF RARE DISEASE
GrantCommon Stock 24,808 $0.00 $0.00
Disclosure

SEC source: 0001846487-25-000002 · wk-form4_1739927844.xml · nonDerivative · entry 1

Mutz Christopher · CIK 0001846487 · HEAD OF RARE DISEASE

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 101,585

F1 · kind: Represents a restricted stock award that will vest in four equal annual installments on the first, second, third and fourth anniversaries of February 12, 2025.

Read SEC document
February 12, 2025 Filed Feb 19, 2025 01:16 UTC
Lalwani NikhilDirector · PRESIDENT & CEO
GrantCommon Stock 60,932 $0.00 $0.00
Disclosure

SEC source: 0001822629-25-000002 · wk-form4_1739927772.xml · nonDerivative · entry 2

Lalwani Nikhil · CIK 0001822629 · Director · PRESIDENT & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 522,709

F2 · kind: These shares represent performance stock units, which will vest over the applicable performance period based on the achievement of the provided performance targets, as set forth in the governing award agreement, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting.

Read SEC document
February 12, 2025 Filed Feb 19, 2025 01:16 UTC
Lalwani NikhilDirector · PRESIDENT & CEO
GrantCommon Stock 91,399 $0.00 $0.00
Disclosure

SEC source: 0001822629-25-000002 · wk-form4_1739927772.xml · nonDerivative · entry 1

Lalwani Nikhil · CIK 0001822629 · Director · PRESIDENT & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 461,777

F1 · kind: Represents a restricted stock award that will vest in four equal annual installments on the first, second, third and fourth anniversaries of February 12, 2025.

Read SEC document
February 12, 2025 Filed Feb 19, 2025 01:15 UTC
Gutwerg OriSVP, GENERICS
GrantCommon Stock 10,444 $0.00 $0.00
Disclosure

SEC source: 0001846478-25-000003 · wk-form4_1739927699.xml · nonDerivative · entry 2

Gutwerg Ori · CIK 0001846478 · SVP, GENERICS

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 103,339

F2 · kind: These shares represent performance stock units, which will vest over the applicable performance period based on the achievement of the provided performance targets, as set forth in the governing award agreement, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting.

Read SEC document
February 12, 2025 Filed Feb 19, 2025 01:15 UTC
Gutwerg OriSVP, GENERICS
GrantCommon Stock 15,668 $0.00 $0.00
Disclosure

SEC source: 0001846478-25-000003 · wk-form4_1739927699.xml · nonDerivative · entry 1

Gutwerg Ori · CIK 0001846478 · SVP, GENERICS

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 92,895

F1 · kind: Represents a restricted stock award that will vest in four equal annual installments on the first, second, third and fourth anniversaries of February 12, 2025.

Read SEC document
February 12, 2025 Filed Feb 19, 2025 01:14 UTC
Gassert ChadSVP - CORP. DEV. & STRATEGY
GrantCommon Stock 9,574 $0.00 $0.00
Disclosure

SEC source: 0001871002-25-000002 · wk-form4_1739927639.xml · nonDerivative · entry 2

Gassert Chad · CIK 0001871002 · SVP - CORP. DEV. & STRATEGY

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 73,615

F2 · kind: These shares represent performance stock units, which will vest over the applicable performance period based on the achievement of the provided performance targets, as set forth in the governing award agreement, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting.

Read SEC document
February 12, 2025 Filed Feb 19, 2025 01:14 UTC
Gassert ChadSVP - CORP. DEV. & STRATEGY
GrantCommon Stock 14,362 $0.00 $0.00
Disclosure

SEC source: 0001871002-25-000002 · wk-form4_1739927639.xml · nonDerivative · entry 1

Gassert Chad · CIK 0001871002 · SVP - CORP. DEV. & STRATEGY

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 64,041

F1 · kind: Represents a restricted stock award that will vest in four equal annual installments on the first, second, third and fourth anniversaries of February 12, 2025.

Read SEC document
February 12, 2025 Filed Feb 19, 2025 01:13 UTC
Davis KristaSVP, CHIEF HR OFFICER
GrantCommon Stock 8,704 $0.00 $0.00
Disclosure

SEC source: 0001946439-25-000002 · wk-form4_1739927578.xml · nonDerivative · entry 2

Davis Krista · CIK 0001946439 · SVP, CHIEF HR OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 70,820

F2 · kind: These shares represent performance stock units, which will vest over the applicable performance period based on the achievement of the provided performance targets, as set forth in the governing award agreement, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting.

Read SEC document
February 12, 2025 Filed Feb 19, 2025 01:13 UTC
Davis KristaSVP, CHIEF HR OFFICER
GrantCommon Stock 13,057 $0.00 $0.00
Disclosure

SEC source: 0001946439-25-000002 · wk-form4_1739927578.xml · nonDerivative · entry 1

Davis Krista · CIK 0001946439 · SVP, CHIEF HR OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 62,116

F1 · kind: Represents a restricted stock award that will vest in four equal annual installments on the first, second, third and fourth anniversaries of February 12, 2025.

Read SEC document
February 12, 2025 Filed Feb 19, 2025 01:12 UTC
Cook MeredithSR. VP, GENERAL COUNSEL & SEC.
GrantCommon Stock 11,316 $0.00 $0.00
Disclosure

SEC source: 0001938861-25-000004 · wk-form4_1739927525.xml · nonDerivative · entry 2

Cook Meredith · CIK 0001938861 · SR. VP, GENERAL COUNSEL & SEC.

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 83,878

F2 · kind: These shares represent performance stock units, which will vest over the applicable performance period based on the achievement of the provided performance targets, as set forth in the governing award agreement, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting.

Read SEC document
February 12, 2025 Filed Feb 19, 2025 01:12 UTC
Cook MeredithSR. VP, GENERAL COUNSEL & SEC.
GrantCommon Stock 16,974 $0.00 $0.00
Disclosure

SEC source: 0001938861-25-000004 · wk-form4_1739927525.xml · nonDerivative · entry 1

Cook Meredith · CIK 0001938861 · SR. VP, GENERAL COUNSEL & SEC.

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 72,562

F1 · kind: Represents a restricted stock award that will vest in four equal annual installments on the first, second, third and fourth anniversaries of February 12, 2025.

Read SEC document
February 12, 2025 Filed Feb 19, 2025 01:11 UTC GrantCommon Stock 16,538 $0.00 $0.00
Disclosure

SEC source: 0001674236-25-000002 · wk-form4_1739927467.xml · nonDerivative · entry 2

CAREY STEPHEN P. · CIK 0001674236 · SVP & CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 195,814

F2 · kind: These shares represent performance stock units, which will vest over the applicable performance period based on the achievement of the provided performance targets, as set forth in the governing award agreement, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting.

Read SEC document
February 12, 2025 Filed Feb 19, 2025 01:11 UTC GrantCommon Stock 24,808 $0.00 $0.00
Disclosure

SEC source: 0001674236-25-000002 · wk-form4_1739927467.xml · nonDerivative · entry 1

CAREY STEPHEN P. · CIK 0001674236 · SVP & CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 179,276

F1 · kind: Represents a restricted stock award that will vest in four equal annual installments on the first, second, third and fourth anniversaries of February 12, 2025.

Read SEC document
January 13, 2025 Filed Jan 13, 2025 21:15 UTC
Cook MeredithSR. VP, GENERAL COUNSEL & SEC.
SaleCommon Stock 400 $53.92 $21,568.00
Disclosure

SEC source: 0001938861-25-000002 · wk-form4_1736802904.xml · nonDerivative · entry 1

Cook Meredith · CIK 0001938861 · SR. VP, GENERAL COUNSEL & SEC.

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 55,588

F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 17, 2024.

Read SEC document
December 17, 2024 Filed Dec 18, 2024 22:59 UTC SaleCommon Stock 7,500 $55.79 $418,425.00
Disclosure

SEC source: 0001674236-24-000015 · wk-form4_1734562739.xml · nonDerivative · entry 1

CAREY STEPHEN P. · CIK 0001674236 · SVP & CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 154,468

F1 · price: The shares were sold in multiple trades at prices ranging from $55.29 to $56.30. The price reported above reflects the weighted average sales price.

Read SEC document
December 13, 2024 Filed Dec 16, 2024 21:20 UTC
Cook MeredithSR. VP, GENERAL COUNSEL & SEC.
SaleCommon Stock 250 $56.24 $14,060.00
Disclosure

SEC source: 0001938861-24-000032 · wk-form4_1734384022.xml · nonDerivative · entry 1

Cook Meredith · CIK 0001938861 · SR. VP, GENERAL COUNSEL & SEC.

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 55,988

F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 11, 2023.

Read SEC document
December 11, 2024 Filed Dec 12, 2024 22:08 UTC
Davis KristaSVP, CHIEF HR OFFICER
SaleCommon Stock 1,000 $60.00 $60,000.00
Disclosure

SEC source: 0001946439-24-000008 · wk-form4_1734041311.xml · nonDerivative · entry 1

Davis Krista · CIK 0001946439 · SVP, CHIEF HR OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 49,059

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 23, 2024.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.